EA200970022A1 - COMBINED PREPARATIONS CONTAINING BIFEPRUNOX AND L-DOSP - Google Patents

COMBINED PREPARATIONS CONTAINING BIFEPRUNOX AND L-DOSP

Info

Publication number
EA200970022A1
EA200970022A1 EA200970022A EA200970022A EA200970022A1 EA 200970022 A1 EA200970022 A1 EA 200970022A1 EA 200970022 A EA200970022 A EA 200970022A EA 200970022 A EA200970022 A EA 200970022A EA 200970022 A1 EA200970022 A1 EA 200970022A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bifeprunox
dosp
preparations containing
combined preparations
dopa
Prior art date
Application number
EA200970022A
Other languages
Russian (ru)
Other versions
EA014576B1 (en
Inventor
Эндрю К. Маккрири
Гюстаф Й.М. Ван Схарренбург
Мартинус Т.М. Тюлп
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA200970022A1 publication Critical patent/EA200970022A1/en
Publication of EA014576B1 publication Critical patent/EA014576B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретение касается применения сочетания препарата бифепрунокса или его N-оксида или фармакологически приемлемых солей указанных соединений и L-допы для одновременного, раздельного или последовательного применения при лечении расстройств, требующих восстановления функции дофаминергической системы, в частности при болезни Паркинсона и при синдроме беспокойных ног.The invention relates to the use of a combination of a bifeprunox preparation or its N-oxide or pharmacologically acceptable salts of these compounds and L-dopa for simultaneous, separate or sequential use in the treatment of disorders requiring restoration of the function of the dopaminergic system, in particular with Parkinson's disease and with restless legs syndrome.

EA200970022A 2006-06-16 2007-06-15 Combination preparations comprising biferpronox and l-dopa EA014576B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405206P 2006-06-16 2006-06-16
EP06115587 2006-06-16
PCT/EP2007/055956 WO2007144422A2 (en) 2006-06-16 2007-06-15 Combination preparations comprising bifeprunox and l-dopa

Publications (2)

Publication Number Publication Date
EA200970022A1 true EA200970022A1 (en) 2009-06-30
EA014576B1 EA014576B1 (en) 2010-12-30

Family

ID=38691894

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970022A EA014576B1 (en) 2006-06-16 2007-06-15 Combination preparations comprising biferpronox and l-dopa

Country Status (9)

Country Link
EP (1) EP2037964A2 (en)
JP (1) JP2009539942A (en)
KR (1) KR20090033871A (en)
AU (1) AU2007259256A1 (en)
CA (1) CA2654557A1 (en)
EA (1) EA014576B1 (en)
IL (1) IL195493A0 (en)
NO (1) NO20090165L (en)
WO (1) WO2007144422A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2670272C2 (en) * 2012-04-18 2018-10-22 Контера Фарма Апс Oral pharmaceutical composition suitable for improving effectiveness of treatment of motor disorders

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009265760B2 (en) * 2008-06-30 2013-07-18 Novartis Ag Combinations comprising mGluR modulators for the treatment of parkinson's disease
ITMI20100260A1 (en) * 2010-02-19 2011-08-20 Giulio Scigliano PHARMACEUTICAL COMPOSITION CONTAINING A DRUG TO REDUCE THE SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS
RU2611376C2 (en) * 2010-10-15 2017-02-21 Контера Фарма Апс Pharmaceutical composition for treating, preventing or relieving movement disorders and its application
PT3209302T (en) 2014-10-21 2019-07-19 Abbvie Inc Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045362A1 (en) * 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2670272C2 (en) * 2012-04-18 2018-10-22 Контера Фарма Апс Oral pharmaceutical composition suitable for improving effectiveness of treatment of motor disorders

Also Published As

Publication number Publication date
CA2654557A1 (en) 2007-12-21
JP2009539942A (en) 2009-11-19
AU2007259256A1 (en) 2007-12-21
IL195493A0 (en) 2009-09-01
WO2007144422A2 (en) 2007-12-21
WO2007144422A3 (en) 2008-03-13
NO20090165L (en) 2009-01-12
EP2037964A2 (en) 2009-03-25
KR20090033871A (en) 2009-04-06
EA014576B1 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
LU93321I2 (en) IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
EA200971107A1 (en) CATECHOLAMINE DERIVATIVES, USEFUL FOR THE TREATMENT OF PARKINSON'S Disease
MX2009002196A (en) Buprenophine-wafer for drug substitution therapy.
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
EA201170527A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING BORONIC ACID COMPOUNDS
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
MY146429A (en) 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e-]-[1,2,4]-triazolo-[1,5-c-]-pyrimidin-5-amine
BRPI0618239A8 (en) use of flibanserin for the treatment of premenopausal sexual desire disorders
BRPI0507966A (en) use of meloxicam for the treatment of respiratory diseases in pigs
MY156822A (en) Indole derivatives as s1p1 receptor agonists
EA200601777A1 (en) NEW APPLICATION OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PATIENTS WITH PATIENTS WITH DIABETIC DIABETIC NEUROPATHY
EA200801826A1 (en) DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICINES CONTAINING INDICATED COMPOUNDS
EA200901423A1 (en) BENZIMIDAZOLY AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
EA200970022A1 (en) COMBINED PREPARATIONS CONTAINING BIFEPRUNOX AND L-DOSP
CL2008003537A1 (en) 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain.
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
CL2009001267A1 (en) Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis.
CL2007001517A1 (en) Compounds derived from carboxamide; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain, in therapy of functional gastrointestinal disorders, irritable bowel syndrome, cancer, parkinson's, Alzheimer's, cardiovascular disorders.
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
CL2007000789A1 (en) Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.
EA201070195A1 (en) DERIVATIVES 1,2,3,4-TETRAGIDROPYRROLO [1,2-A] PIRAZIN-6-CARBOXAMIDES AND 2,3,4,5-TETRAHYDROPYRROLO [1,2-a] [1,4] -DIAZEPIN-7-CARBOXAMIDES , THEIR RECEIVING AND THEIR APPLICATION IN THERAPY
DK1786442T3 (en) Treatment of neurodegenerative diseases using DEGS inhibitors
UY31131A1 (en) "SUBSTITUTED OXAZOLIDINONES AND ITS USE
EA200970021A1 (en) COMBINED PREPARATIONS CONTAINING SLV308 AND L-DOPA

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU